EA012036B1 - Мемантин для лечения расстройств поведения детского возраста - Google Patents

Мемантин для лечения расстройств поведения детского возраста Download PDF

Info

Publication number
EA012036B1
EA012036B1 EA200700708A EA200700708A EA012036B1 EA 012036 B1 EA012036 B1 EA 012036B1 EA 200700708 A EA200700708 A EA 200700708A EA 200700708 A EA200700708 A EA 200700708A EA 012036 B1 EA012036 B1 EA 012036B1
Authority
EA
Eurasian Patent Office
Prior art keywords
memantine
disorder
subjects
day
dose
Prior art date
Application number
EA200700708A
Other languages
English (en)
Russian (ru)
Other versions
EA200700708A1 (ru
Inventor
Джеффри Джонас
Прадип К. Банерджи
Сандип Гупта
Аллисон Манн
Ханс-Йорг Мебиус
Original Assignee
Мерц Фарма Гмбх Унд Ко. Кгаа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35445934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA012036(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерц Фарма Гмбх Унд Ко. Кгаа filed Critical Мерц Фарма Гмбх Унд Ко. Кгаа
Publication of EA200700708A1 publication Critical patent/EA200700708A1/ru
Publication of EA012036B1 publication Critical patent/EA012036B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA200700708A 2004-09-23 2005-09-23 Мемантин для лечения расстройств поведения детского возраста EA012036B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61260004P 2004-09-23 2004-09-23
PCT/US2005/034199 WO2006034465A1 (fr) 2004-09-23 2005-09-23 Memantine pour le traitement des troubles du comportement de l'enfant

Publications (2)

Publication Number Publication Date
EA200700708A1 EA200700708A1 (ru) 2007-08-31
EA012036B1 true EA012036B1 (ru) 2009-06-30

Family

ID=35445934

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700708A EA012036B1 (ru) 2004-09-23 2005-09-23 Мемантин для лечения расстройств поведения детского возраста

Country Status (16)

Country Link
US (2) US20060079582A1 (fr)
EP (1) EP1799224A1 (fr)
JP (1) JP2008514620A (fr)
KR (1) KR20070046185A (fr)
CN (1) CN101374525A (fr)
AR (1) AR052643A1 (fr)
AU (1) AU2005286672B2 (fr)
BR (1) BRPI0515560A (fr)
CA (1) CA2578953A1 (fr)
EA (1) EA012036B1 (fr)
IL (1) IL182105A0 (fr)
MX (1) MX2007003267A (fr)
NO (1) NO20072035L (fr)
TW (1) TW200626160A (fr)
WO (1) WO2006034465A1 (fr)
ZA (1) ZA200702130B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014054965A1 (fr) 2012-10-01 2014-04-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Moyen pour la prévention et le traitement de troubles comportementaux, psychiques et cognitifs

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
EP2040676A2 (fr) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Formulations à dissolution orale de mémantine
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
WO2009004440A2 (fr) * 2007-06-29 2009-01-08 Orchid Chemicals & Pharmaceuticals Limited Compositions à dissolution rapide de chlorhydrate de mémantine
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (fr) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Compositions pharmaceutiques comportant des dérivés d'aminoadamantane
US20100144863A1 (en) * 2008-12-08 2010-06-10 Bernard Hublot Compounds and methods for treating autism spectrum disorders
IT1396556B1 (it) 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
CN103313712B (zh) 2010-11-15 2016-10-26 艾吉因生物股份有限公司 用于治疗认知障碍的哒嗪衍生物、组合物和方法
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
US9242009B2 (en) 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
KR101424514B1 (ko) * 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
EP2948135B1 (fr) * 2013-01-25 2019-01-02 Case Western Reserve University Compositions et méthodes de traitement de troubles envahissants du développement
WO2014153180A1 (fr) * 2013-03-14 2014-09-25 Michela Gallagher Procédés et compositions pour améliorer la fonction cognitive
JP6883988B2 (ja) 2013-12-20 2021-06-09 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
BR112017024777A2 (pt) * 2015-05-22 2018-08-07 Univ Arizona State uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
IL256354B (en) 2015-06-19 2022-09-01 Agenebio Inc History of benzodiazepines, preparations and their use for the treatment of cognitive impairment
CA3032996A1 (fr) 2016-08-24 2018-03-01 Zogenix International Limited Formulation pour l'inhibition d'agonistes de 5-ht2b et procedes pour leur utilisation
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN111356452A (zh) * 2017-08-01 2020-06-30 斯图尔特·A·利普顿 用于治疗神经病况的方法和组合物
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
WO1999036064A2 (fr) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methodes de traitement de la dyskinesie tardive et autres perturbations des mouvements
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US20010044446A1 (en) * 1999-12-08 2001-11-22 Phillips John A. Modulation of in vivo glutamine and glycine levels in the treatment of autism
WO2003061656A1 (fr) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
WO2004009062A2 (fr) * 2002-07-19 2004-01-29 Khalid Iqbal Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau
WO2005084655A1 (fr) * 2004-03-03 2005-09-15 Merz Pharma Gmbh & Co. Kgaa Derives de 1-aminocyclohexane pour le traitement de l'agitation et d'autres troubles du comportement, en particulier ceux qui sont associes a la maladie d'alzheimer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH603545A5 (fr) * 1972-04-20 1978-08-31 Merz & Co
HU169986B (fr) * 1972-12-07 1977-03-28
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
EP0392059B1 (fr) * 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Utilisation de dérivés de l'adamantane pour la prévention et le traitement de l'ischémie cérébrale
US6326226B1 (en) * 1997-07-15 2001-12-04 Lg. Philips Lcd Co., Ltd. Method of crystallizing an amorphous film
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
WO1999036064A2 (fr) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methodes de traitement de la dyskinesie tardive et autres perturbations des mouvements
US20010044446A1 (en) * 1999-12-08 2001-11-22 Phillips John A. Modulation of in vivo glutamine and glycine levels in the treatment of autism
WO2003061656A1 (fr) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
WO2004009062A2 (fr) * 2002-07-19 2004-01-29 Khalid Iqbal Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau
WO2005084655A1 (fr) * 2004-03-03 2005-09-15 Merz Pharma Gmbh & Co. Kgaa Derives de 1-aminocyclohexane pour le traitement de l'agitation et d'autres troubles du comportement, en particulier ceux qui sont associes a la maladie d'alzheimer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEZ M.G. ET AL.: "Neurologic treatment strategies in autism: An overview of medical intervention strategies" SEMINARS IN PEDIATRIC NEUROLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 11, no. 3, September 2004 (2004-09), pages 229-235, XP004666246, ISSN: 1071-9091, page 230, left-hand column, paragraph 4 *
CHEZ MICHAEL G. ET AL.: "Memantine experience in children and adolescents with autistic spectrum disorders" ANNALS OF NEUROLOGY, vol. 56, no. Suppl. 8, 2004, page S109, XP009058844 & 33RD ANNUAL MEETING OF THE CHILD-NEUROLOGY-SOCIETY; TORONTO, CANADA; OCTOBER 13-16, 2004 ISSN: 0364-5134, abstract *
SUKHANOV I.M. ET AL.: "EFFECTS OF NMDA RECEPTOR CHANNEL BLOCKERS, MK-801 AND MEMANTINE, ON LOCOMOTOR ACTIVITY AND TOLERANCE TO DELAY OF REWARD IN WISTAR-KYOTO AND SPONTANEOUSLY HYPERTENSIVE RATS" BEHAVIOURAL PHARMACOLOGY, RAPID SCIENCE, PUBLISHERS, GB, vol. 15, no. 4, July 2004 (2004-07), pages 263-271, XP009048169, ISSN: 0955-8810, page 270, right-hand column, last paragraph *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014054965A1 (fr) 2012-10-01 2014-04-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Moyen pour la prévention et le traitement de troubles comportementaux, psychiques et cognitifs

Also Published As

Publication number Publication date
US20100081723A1 (en) 2010-04-01
EA200700708A1 (ru) 2007-08-31
CN101374525A (zh) 2009-02-25
AU2005286672A1 (en) 2006-03-30
AR052643A1 (es) 2007-03-28
NO20072035L (no) 2007-06-13
AU2005286672B2 (en) 2009-03-12
EP1799224A1 (fr) 2007-06-27
WO2006034465A1 (fr) 2006-03-30
WO2006034465A8 (fr) 2006-06-08
IL182105A0 (en) 2007-07-24
US20060079582A1 (en) 2006-04-13
TW200626160A (en) 2006-08-01
ZA200702130B (en) 2008-09-25
BRPI0515560A (pt) 2008-07-29
KR20070046185A (ko) 2007-05-02
MX2007003267A (es) 2007-05-23
JP2008514620A (ja) 2008-05-08
CA2578953A1 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
EA012036B1 (ru) Мемантин для лечения расстройств поведения детского возраста
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
Dopheide et al. Attention‐deficit‐hyperactivity disorder: an update
ZUDDAS et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation
Heller et al. Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study
US20220409597A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
Durand-Rivera et al. Methylphenidate efficacy: immediate versus extended release at short term in Mexican children with ADHD assessed by Conners scale and EEG
CA3124416C (fr) Schemas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du systeme nerveux central dopaminergiques
Hollander et al. Clinical manual for the treatment of autism
Pallanti et al. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine
US20210283075A1 (en) Methods of treating attention deficit hyperactivity disorder
Madhusoodanan et al. Psychiatric symptoms of progressive supranuclear palsy: a case report and brief review
Mooney et al. Psychopharmacology of autism spectrum disorders
US20230059709A1 (en) Treatment of fragile x syndrome with cannabidiol
Mooney et al. Psychopharmacology Chapter
AU2011235981B2 (en) Use of Memantine (Namenda) to Treat Autism, Compulsivity, and Impulsivity
Broadstock et al. The effectiveness of pharmacological therapies for young people and adults with Autism Spectrum Disorder (ASD)
Manjuprasad A Comparative Study of the Efficacy and Tolerability of Risperidone and Olanzapine as Add-On Therapy in Patients with Bipolar Affective Disorder–A Prospective, Naturalistic, Hospital Based Clinical Study
Bebchuk et al. Neurobiology of social phobia

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU